XM无法为美国居民提供服务。

GSK sues Moderna for US patent infringement over COVID, RSV vaccines



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-GSK sues Moderna for US patent infringement over COVID, RSV vaccines</title></head><body>

Moderna to defend against GSK's claims, spokesperson says

GSK seeks unspecified monetary damages from Moderna

Adds information about RSV vaccine claims in paragraphs 1 and 6

By Blake Brittain

Oct 15 (Reuters) -British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia.

According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer PFE.N and BioNTech 22UAy.DE in the same court in April over their COVID-19 vaccine. The new litigation seeks unspecified monetary damages.

A spokesperson for Massachusetts-based Moderna said the company was aware of the lawsuits and would defend itself against the claims.

GSK is "willing to license these patents on commercially reasonable terms and to ensure continued patient access," a company spokesperson said.

The lawsuits add to a web of U.S. court cases involving Pfizer, BioNTech and Moderna over patent royalties for technology used in their COVID vaccines, including one brought by Moderna against Pfizer in 2022.

Moderna earned $6.7 billion in revenue from Spikevax last year. Pfizer made $11.2 billion from sales of Comirnaty, the COVID vaccine it developed with German partner BioNTech. Sales of both vaccines declined significantly last year from 2022.

GSK also sued Pfizer for patent infringement over its RSV shot Abrysvo last year. The U.S. Food and Drug Administration approved Moderna's RSV vaccine in May.

GSK said in the new cases that its patents cover technology pioneered in 2008 that provides "the foundation for Moderna's mRNA vaccine portfolio." GSK said it bought the rights to the inventions when it acquired part of Novartis' NOVN.S vaccine business in 2015.


Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK ID:nL1N3L60U6

Moderna forecasts lower sales next year, shares near four-year low ID:nL1N3KU0BN


Reporting by Blake Brittain
Editing by David Bario, Will Dunham and Bill Berkrot

</body></html>

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明